,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2014-02-20 03:00:00,"Omeros Corporation ( OMER ) announced that the first patient has been dosed in a second phase II study on candidate, OMS824.",0.3688408136367798,0.009732605889439583,0.6214265823364258,neutral,0.35910820960998535
1,2014-02-20 03:00:00,Omeros is evaluating OMS824 for the treatment of patients with symptomatic Huntington's disease (HD).,0.31380635499954224,0.010558600537478924,0.675635039806366,neutral,0.30324774980545044
2,2014-02-20 03:00:00,OMS824 is Omeros' lead candidate in its phosphodiesterase 10 (PDE10) program.,0.4025328457355499,0.008497764356434345,0.5889694094657898,neutral,0.39403507113456726
3,2014-02-20 03:00:00,This phase II study will randomize patients to receive placebo or one of three doses of OMS824.,0.08062445372343063,0.007088076788932085,0.9122874140739441,neutral,0.07353637367486954
4,2014-02-20 03:00:00,"The study will evaluate the tolerability, safety, pharmacokinetics of OMS824.",0.0994408056139946,0.005909537430852652,0.8946496248245239,neutral,0.09353126585483551
5,2014-02-20 03:00:00,"The efficacy of OMS824 will be assessed across three functional domains: motor, cognitive and behavior.",0.04434983432292938,0.006189287174493074,0.9494608044624329,neutral,0.038160547614097595
6,2014-02-20 03:00:00,Omeros expects interim results in the second half of 2014 and final results in 2015.,0.028737368062138557,0.0073769185692071915,0.9638857245445251,neutral,0.021360449492931366
7,2014-02-20 03:00:00,We note that the candidate enjoys Orphan Drug and Fast Track designation in the U.S. for HD.,0.845698893070221,0.017153369262814522,0.1371476948261261,positive,0.8285455107688904
8,2014-02-20 03:00:00,"Last month, Omeros provided positive results from a phase IIa study on OMS824, which is being evaluated for the treatment of schizophrenia.",0.9173650741577148,0.018631909042596817,0.06400295346975327,positive,0.8987331390380859
9,2014-02-20 03:00:00,The study demonstrated that OMS824 showed systemic pharmacokinetics when administered alone and concurrently with approved antipsychotic agents in schizophrenic patients.,0.33292627334594727,0.012425332330167294,0.6546483635902405,neutral,0.3205009400844574
10,2014-02-20 03:00:00,A Fast Track application is also under review in the U.S. for OMS824 for the treatment of schizophrenia.,0.2024996131658554,0.023635391145944595,0.7738649845123291,neutral,0.1788642257452011
11,2014-02-20 03:00:00,We are encouraged by the pipeline progress at Omeros.,0.9055236577987671,0.013501529581844807,0.08097482472658157,positive,0.8920221328735352
12,2014-02-20 03:00:00,Omeros' most advanced and proprietary pharmacosurgery candidate is Omidria.,0.32771387696266174,0.007747746538370848,0.6645384430885315,neutral,0.3199661374092102
13,2014-02-20 03:00:00,The company is looking to get Omidria approved in the U.S. and EU for the treatment of patients undergoing intraocular lens replacement surgery.,0.8296232223510742,0.01438475213944912,0.1559920459985733,positive,0.8152384757995605
14,2014-02-20 03:00:00,Omeros expects to market Omidria in the second half of 2014 on approval.,0.3485969603061676,0.007793969474732876,0.6436089873313904,neutral,0.34080299735069275
15,2014-02-20 03:00:00,Omeros currently carries a Zacks Rank #3 (Hold).,0.032044582068920135,0.017477478832006454,0.9504778981208801,neutral,0.014567103236913681
16,2014-02-20 03:00:00,Investors looking for better-ranked stocks in the biopharma sector may consider companies like Endocyte Inc .,0.4325006604194641,0.027857400476932526,0.5396419167518616,neutral,0.4046432673931122
17,2014-02-20 03:00:00,"( ECYT ), Actelion Ltd. ( ALIOF ) and Biogen Idec Inc. ( BIIB ).",0.015985161066055298,0.006758049130439758,0.9772567749023438,neutral,0.00922711193561554
18,2014-02-20 03:00:00,Endocyte and Biogen carry a Zacks Rank #1 (Strong Buy) while Actelion carries a Zacks Rank #2 (Buy).,0.353633850812912,0.015863087028265,0.6305031180381775,neutral,0.3377707600593567
19,2014-02-20 03:00:00,To read this article on Zacks.com click here.,0.017961200326681137,0.01924508437514305,0.9627937078475952,neutral,-0.001283884048461914
20,2014-02-20 03:00:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.015637893229722977,0.9741575717926025,neutral,-0.0054333265870809555
